Department of Health and Human Services, National Institutes of Health

Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)

Who can apply

Special district governments
Public and state-controlled colleges
Public and tribal housing authorities
Private colleges and universities
Small businesses
Others (see eligibility details)
County governments
Independent school districts
City or township governments
Federally recognized tribal governments
Nonprofits with 501(c)(3) status
Tribal organizations
Nonprofits without 501(c)(3) status
For-profit organizations (not small businesses)
State governments

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

About this grant

The purpose of this announcement is to encourage investigators to pursue translational activities and clinical feasibility studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent clinical feasibility study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress. Participants in Blueprint MedTech receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants to receive assistance with specialty areas including regulatory, reimbursement, intellectual property, commercialization, and strategic partnerships. Participants can also augment their project with NIH contract research organizations that specialize in large animal testing, sterilization testing, biocompatibility assessment, manufacturing, and medical monitoring. Individuals, institutions, or businesses developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to this NOFO or any of the companion opportunities. For more information see BP MedTech website.

Who has won this before

These awards are for each Assistance Listing as a whole, which may cover multiple opportunities.

Largest recent recipients, ranked by total award amount across the Assistance Listings below. Amounts may include funding outside the stated period; years are award start years.

Showing 10 of 50 recorded recipient rows. Follow the program links for more recipients, or search all awards on USAspending.gov using the Assistance Listing number.

Assistance Listing 93.121

2,549awards with funding activity in the last 3 completed federal fiscal years, 2024–2026 (October 1, 2023 to September 30, 2026). Total awarded during this period: $1,138,898,100.64 in net obligations (funding committed, less reductions).

FRED HUTCHINSON CANCER CENTER$443,702,768.16Place of performance: WashingtonStarted 2006

Most awards went to California, Pennsylvania, and Massachusetts, ranked by dollars obligated at the place of performance across all matching awards.

Past rounds and recipients of this program (93.121)